Legal Advantage Investments Inc. Purchases New Shares in Natera, Inc. $NTRA

Legal Advantage Investments Inc. purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the second quarter, HoldingsChannel.com reports. The firm purchased 3,500 shares of the medical research company’s stock, valued at approximately $591,000.

Several other hedge funds also recently added to or reduced their stakes in NTRA. Bank of Jackson Hole Trust acquired a new position in Natera during the 1st quarter worth $29,000. Rakuten Securities Inc. grew its holdings in Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock worth $31,000 after acquiring an additional 119 shares in the last quarter. ORG Partners LLC acquired a new position in Natera during the 1st quarter worth $32,000. TCTC Holdings LLC grew its holdings in Natera by 114.8% during the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after acquiring an additional 124 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after acquiring an additional 106 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Trading Down 2.2%

NTRA stock opened at $169.27 on Friday. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $183.00. The company has a market capitalization of $23.23 billion, a price-to-earnings ratio of -88.62 and a beta of 1.74. The firm’s 50-day moving average is $164.58 and its two-hundred day moving average is $157.27.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same quarter last year, the firm posted ($0.30) earnings per share. The firm’s quarterly revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NTRA shares. Royal Bank Of Canada set a $268.00 price objective on shares of Natera and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Wednesday. Cowen restated a “buy” rating on shares of Natera in a research report on Friday, August 8th. Barclays restated an “overweight” rating and issued a $210.00 price target (up from $190.00) on shares of Natera in a research report on Friday, August 8th. Finally, Stephens restated an “overweight” rating and issued a $183.00 price target on shares of Natera in a research report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $192.88.

Insider Activity at Natera

In other Natera news, insider John Fesko sold 678 shares of the business’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $155.46, for a total transaction of $105,401.88. Following the sale, the insider directly owned 152,747 shares in the company, valued at approximately $23,746,048.62. The trade was a 0.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 14,083 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $160.00, for a total transaction of $2,253,280.00. Following the sale, the chief executive officer owned 154,072 shares in the company, valued at $24,651,520. This trade represents a 8.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 72,464 shares of company stock worth $10,963,125 in the last three months. Insiders own 5.63% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.